DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal

Dow Jones

04/30

By Kelly Cloonan

DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista Therapeutics as KalVista plots a potential sale.

DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday.

DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal.

The company said it hasn't determined any actions it may take regarding the deal.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 29, 2026 18:12 ET (22:12 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2631422527"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631422527\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631422527?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631422527","market":"sg","top_or_hot":-1,"title":"DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> as KalVista plots a potential sale. \n</p>\n<p>\n  DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday. \n</p>\n<p>\n  DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal. \n</p>\n<p>\n  The company said it hasn't determined any actions it may take regarding the deal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 18:12 ET (22:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-30 06:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> as KalVista plots a potential sale. \n</p>\n<p>\n  DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday. \n</p>\n<p>\n  DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal. \n</p>\n<p>\n  The company said it hasn't determined any actions it may take regarding the deal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 18:12 ET (22:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128526141.USD","symbol_name":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631422527","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631422527","pubTimestamp":1777500720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista Therapeutics as KalVista plots a potential sale.DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday.DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal.The company said it hasn't determined any actions it may take regarding the deal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","DRI":"达登饭店","BK4209":"餐馆","XLV":"健康照护类股ETF-SPDR","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4137":"综合支持服务","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","BK4588":"碎股","XBI":"SPDR S&P Biotech ETF","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","KALV":"Kalvista Pharmaceuticals Inc","BK4581":"高盛持仓","BK4139":"生物科技","BK4504":"桥水持仓","HCSG":"Healthcare Svcs Group Inc"},"translate_title":"DRI Healthcare Trust在Chiesi交易提案后评估与KalVista的特许权使用费协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":0.6,"XLV":1.5,"DRI":1.5,"KALV":0.9,"XBI":0.6,"HCSG":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  DRI Healthcare Trust is evaluating its rights and obligations under its royalty agreement with KalVista Therapeutics as KalVista plots a potential sale. \n\n\n  DRI Healthcare said Wednesday its royalty agreement with KalVista, which entitles it to worldwide net sales of all formulations of Ekterly, could change if a deal for Chiesi Group to acquire KalVista closes. KalVista disclosed the proposed sale earlier Wednesday. \n\n\n  DRI Healthcare said it is reviewing the transaction and looking into its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the deal. \n\n\n  The company said it hasn't determined any actions it may take regarding the deal. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 18:12 ET (22:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}